Hoth and Zylö Partner to Develop ‘Natural’ Cannabis-like Treatment for Lupus Skin Lesions

Hoth and Zylö Partner to Develop ‘Natural’ Cannabis-like Treatment for Lupus Skin Lesions

Hoth Therapeutics and Zylö Therapeutics entered into an agreement to jointly develop an endocannabinoid-based treatment for cutaneous lupus erythematosus (CLE), a lupus subtype that affects the skin.

Endocannabinoids are cannabis-like molecules naturally produced by the human body, with similar effects to that of medical marijuana.

The agreement gives Hoth an exclusive North American license to develop and commercialize a possibly topical treatment that delivers an endocannabinoid called anandamide using Zylö’s patented delivery system, called Z-pods.

“We are thrilled to partner with Hoth, an innovative company committed to developing treatment solutions for diseases — such as lupus — with a high unmet clinical need,” Scott Pancoast, CEO of Zylö, said in a press release.

Z-pods are a delivery system that consists of gel-based nanoparticles — microscopic particles that can be loaded with a therapeutic agents. To treat CLE, Z-pods can be directly applied to the top layer of the skin, where they migrate to the deeper layers, delivering their cargo in a controlled and sustained manner.

A single application of Z-pod delivered medication can last eight to 24 hours, Zylö reports on its homepage. After that, the treatment goes away along with dead skin cells. Z-pods lessen the need for frequent applications, and the use of needles or patches to achieve penetration. This delivery system has been especially successful with hard-to-deliver therapies, the company states.

“As we collaborate with the Hoth team to advance [anandamide]-loaded Z-pods through the next stages of development, we expect to further demonstrate the critical role that our patented Z-pod delivery system plays in improving therapeutic outcomes,” Pancoast added.

Researchers at the Albert Einstein College of Medicine, where the therapy was initially developed, reported that Z-pods loaded with anandamide inhibited the development of lesions caused by CLE when applied to the skin of a mouse model of lupus.

The treatment also improved tissue organization, and lessened the accumulation of immune cells in the skin and the production of inflammatory molecules by skin cells.

“Zylö’s initial work with [anandamide]-loaded Z-pods shows significant promise in treating CLE, and we look forward to collaborating with them to bring this treatment to market,” said Robb Knie, CEO of Hoth.

Hoth also acquired some rights to market the formulation in other countries, and to apply it to diseases such as psoriasis and rheumatoid arthritis.

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.
Total Posts: 289
Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
×
Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.
Latest Posts
  • childhood-onset lupus
  • lupus treatment
  • Lupus nephritis
  • Pregnancy Compensation Hypothesis, autoimmune disease

2 comments

  1. Timothy J. Freeman says:

    Is CLE the same as DLE meaning discoid lupus erythamatosis? I have been fighting this for 40 years. It is good to see new breakthroughs in treatments. Lupus is a humiliating disease. Thank god I have always been diagnosed with DLE and not systemic LE.

  2. Jane Davis says:

    I am very glad to hear of this new medicine. I have Subacute Cutaneous Lupus. I’ve experienced only one very bad outbreak. It was horrible.
    Will this new medicine help me?

Leave a Comment

Your email address will not be published. Required fields are marked *